Increasing high-density lipoprotein cholesterol by cholesteryl ester transfer protein-inhibition: a rocky road and lessons learned? The early demise of the dal-HEART programme

Eur Heart J. 2012 Jul;33(14):1712-5. doi: 10.1093/eurheartj/ehs182. Epub 2012 Jun 13.
No abstract available

Publication types

  • Editorial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute Coronary Syndrome / drug therapy
  • Amides
  • Anticholesteremic Agents / therapeutic use
  • Atherosclerosis / prevention & control
  • Cardiovascular Diseases / drug therapy*
  • Cholesterol Ester Transfer Proteins / antagonists & inhibitors*
  • Cholesterol, HDL / metabolism*
  • Early Termination of Clinical Trials
  • Esters
  • Humans
  • Oxazolidinones / therapeutic use
  • Quinolines / therapeutic use
  • Randomized Controlled Trials as Topic
  • Sulfhydryl Compounds / therapeutic use

Substances

  • Amides
  • Anticholesteremic Agents
  • Cholesterol Ester Transfer Proteins
  • Cholesterol, HDL
  • Esters
  • Oxazolidinones
  • Quinolines
  • Sulfhydryl Compounds
  • dalcetrapib
  • torcetrapib
  • anacetrapib

Associated data

  • ClinicalTrials.gov/NCT01252953